Immunogenicity confirmatory testing is the critical second tier in the multi-tiered anti-drug antibody (ADA) evaluation strategy required by global regulatory authorities for biopharmaceutical development. By employing competitive inhibition with excess therapeutic protein, the confirmatory assay demonstrates that samples flagged as positive in screening contain true drug-specific antibodies rather than nonspecific binding signals. This article reviews the scientific principles, sample types, testing items, analytical platforms, validation requirements, and typical applications of immunogenicity confirmatory assays performed in accredited third-party laboratories.
Technical Overview
Immunogenicity refers to the capacity of a therapeutic product—particularly biologics such as monoclonal antibodies, fusion proteins, cytokines, enzymes, and peptide therapeutics—to provoke an immune response in treated patients or animals. This response frequently manifests as the production of anti-drug antibodies (ADA), which may alter pharmacokinetics, reduce efficacy, cause infusion or injection reactions, or, in rare but serious cases, cross-neutralize endogenous protein counterparts.
Because a single assay cannot simultaneously deliver adequate sensitivity and specificity across large study populations, regulatory authorities including the U.S. FDA, the European Medicines Agency (EMA), and China's NMPA mandate a hierarchical, multi-tiered testing strategy:
- Screening assay: detects potentially ADA-positive samples using a statistically derived screening cut point, intentionally tuned to a low false-negative rate (typically 5%).
- Confirmatory assay: verifies the binding specificity of screening-positive samples through competitive inhibition with an excess of unlabeled therapeutic drug.
- Titration assay: semi-quantifies confirmed positive samples by serial dilution to determine a titer.
- Neutralizing antibody (NAb) assay: evaluates whether confirmed ADA can block the pharmacological activity of the drug.
The immunogenicity confirmatory test addresses the core limitation of screening assays—false positives arising from nonspecific matrix interactions, heterophilic antibodies, or target interference. In practice, each sample is analyzed in parallel with and without pre-incubation with excess therapeutic protein. A true ADA-positive sample shows a marked signal reduction in the presence of the competitor, quantified as percent inhibition. Samples exceeding the pre-established confirmatory cut point are reported as confirmed positive.
This testing philosophy is codified in key reference frameworks, including the FDA guidance "Immunogenicity Testing of Therapeutic Protein Products—Developing and Validating Assays for Anti-Drug Antibody Detection," the EMA "Guideline on Immunogenicity Assessment of Therapeutic Proteins," ICH S6(R1) for biotechnology-derived pharmaceuticals, and USP General Chapter <1106> on immunogenicity assays. Accredited third-party laboratories routinely conduct these studies under GLP or GCLP quality systems to support regulatory submissions.
Testing Samples
Human Serum and Plasma Samples
Serum is the preferred matrix for ADA confirmation in clinical trials, collected from healthy volunteers or patients at protocol-defined time points such as baseline, pre-dose, post-infusion, and follow-up visits. Plasma (EDTA or heparin anticoagulated) can be used when matrix equivalence has been demonstrated. Confirmatory testing is generally performed on all screening-positive samples, often including borderline samples and samples near the screening cut point based on the study's data analysis plan.
Animal Serum and Plasma Samples
In preclinical development, confirmatory ADA testing supports GLP toxicology studies, pharmacokinetic/pharmacodynamic (PK/PD) studies, and tissue cross-reactivity interpretations. Common species include mouse, rat, rabbit, dog, and cynomolgus monkey. Species-specific matrix effects must be characterized during assay development because endogenous binding components differ substantially across species.
Sample Handling and Stability Requirements
Proper sample management is essential to preserve ADA integrity and ensure valid confirmation results:
- Collect blood using standardized protocols; allow clotting for serum or process promptly for plasma to minimize hemolysis.
- Aliquot samples to avoid repeated freeze-thaw cycles; store at -20°C or ideally -70°C for long-term archiving.
- Document storage duration and conditions; confirm ADA stability in matrix under intended handling conditions during validation.
- Apply the validated minimum required dilution (MRD) consistently between screening and confirmatory assays.
Testing Items
The scope of an immunogenicity confirmatory study typically encompasses the following deliverables:
- Specificity confirmation: competitive inhibition testing of screening-positive samples with excess unlabeled therapeutic drug.
- Confirmatory cut point determination: statistical establishment of the percent-inhibition threshold distinguishing confirmed positive from negative results, using drug-naive matrix from an adequate number of donors (typically at least 30-50 individuals).
- Percent inhibition reporting: calculation of (1 − signal with competitor / signal without competitor) × 100% for each sample.
- Titration determination: serial dilution analysis of confirmed positives to estimate relative ADA concentration, reported as titer with the assay's screening cut point applied.
- Drug interference and drug tolerance evaluation: assessment of the assay's ability to detect ADA in the presence of circulating therapeutic drug, often mitigated by acid dissociation pretreatment.
- Isotype characterization (optional): determination of ADA isotype or subclass, such as IgG or IgM, when mechanistic understanding is required.
- Neutralizing antibody assessment (subsequent tier): cell-based or ligand-binding NAb assays for confirmed positive samples where clinically warranted.
Testing Methods
The confirmatory assay should ideally use the same platform and format as the screening assay to maintain analytical consistency, with the addition of a competitive inhibition step.
Bridging Assay Formats (ELISA and Electrochemiluminescence)
The bridging format is the most widely adopted approach for whole-ADA detection. The therapeutic drug is labeled with a detectable tag (biotin for capture, ruthenium or enzyme for detection), and bivalent ADA molecules bridge the labeled drug molecules to generate signal. For confirmation, samples are pre-incubated with a large molar excess of unlabeled drug (commonly 10- to 1000-fold, established during development) before analysis. Electrochemiluminescence (ECL) platforms are frequently preferred for clinical studies due to high sensitivity, broad dynamic range, low matrix interference, and good drug tolerance.
Direct and Indirect Binding Formats
For non-bridging configurations—such as indirect ELISA where the drug is coated on a solid phase and bound ADA is detected with a species-specific anti-immunoglobulin reagent—confirmation follows the same competitive inhibition logic, with excess soluble drug competing for ADA binding sites.
Surface Plasmon Resonance (SPR)
Label-free SPR instruments detect real-time binding of ADA to immobilized drug on a sensor chip. Because SPR measures the interaction itself, competition with soluble drug or the kinetics of binding and dissociation can serve as confirmation evidence. SPR is particularly useful for high-affinity antibodies, complex matrices, or when acid dissociation is undesirable.
Confirmatory Cut Point and Data Processing
The confirmatory cut point is derived statistically from the distribution of percent inhibition values in drug-naive matrix, typically at the 99th percentile for a 1% false-positive rate, or the 95th percentile where justified. Both parametric (normal-theory) and non-parametric (distribution-free) approaches may be applied depending on data normality. In many programs, the calculated value is rounded to a convenient operational threshold such as 50% inhibition when the underlying data support this simplification. Floating cut points (run-specific, based on concurrent negative controls) are used when inter-run variability is significant. System suitability is monitored in each run using blank wells, negative controls, and high/low positive controls spiked with and without competitor.
Method Validation Parameters
Validation of the confirmatory assay follows the risk-based expectations of FDA, EMA, and USP guidance and generally includes:
- Specificity: demonstration that multiple ADA-positive samples show reduced signal upon competition, while negative samples remain unaffected.
- Precision: intra-run and inter-run repeatability of percent inhibition for positive controls near the cut point.
- Sensitivity: lowest ADA concentration reliably inhibited, expressed relative to the confirmatory cut point.
- Robustness: tolerance to variations in competitor concentration, incubation time, temperature, and reagent lots.
- Stability: bench-top, freeze-thaw, and long-term storage stability of ADA in matrix, plus competitor reagent stability.
- System suitability criteria: predefined acceptance ranges for controls to qualify each analytical run.
Applications
Immunogenicity confirmatory testing is applied across the entire life cycle of biopharmaceutical products:
- Preclinical development: ADA confirmation in GLP toxicology and PK studies to interpret exposure, clearance, and safety findings in animal models.
- Clinical trials: tiered ADA evaluation in Phase I first-in-human studies through Phase III pivotal trials, informing incidence rates, titers, and relationship to pharmacokinetics, efficacy, and safety.
- Biosimilar development: comparative immunogenicity assessment between biosimilar and reference products, a central element of regulatory approval.
- Biologics modalities: monoclonal antibodies, antibody-drug conjugates, Fc-fusion proteins, therapeutic enzymes, cytokines, growth factors, and synthetic peptides.
- Emerging modalities: adeno-associated virus (AAV) vector gene therapy anti-capsid antibodies, cell therapy support testing, and anti-PEG antibody assessment for pegylated products.
- Post-marketing surveillance and manufacturing changes: monitoring ADA incidence after approval and demonstrating immunogenicity comparability following process modifications.
- Regulatory submissions: generation of auditable, GLP/GCLP-compliant packages accepted by FDA, EMA, NMPA, and other health authorities.
FAQ
Why is a confirmatory assay necessary when the screening assay is already validated?
Screening assays are deliberately tuned for high sensitivity, which introduces an accepted false-positive rate (typically around 5%) caused by nonspecific matrix components, heterophilic antibodies, or rheumatoid factor. The confirmatory assay establishes that the observed binding is truly drug-specific through competitive inhibition, ensuring that only genuine ADA-positive subjects are counted in incidence calculations and clinical interpretation.
What percent inhibition threshold defines a confirmed positive result?
There is no universal threshold. The confirmatory cut point is derived from the statistical distribution of inhibition values in drug-naive matrix from the relevant population—often the 99th percentile for approximately a 1% false-positive rate. In many validated assays this calculated value is rounded to an operational threshold such as 50% inhibition, but the final criterion must be justified with study data and documented in the validation report.
Are all screening-positive samples tested in the confirmatory assay?
In most clinical protocols, yes—all screening positives are confirmed to accurately establish ADA incidence. Borderline samples near the screening cut point may also be confirmed depending on the predefined statistical analysis plan. In large preclinical studies, confirmation may focus on treatment-emergent positives relative to baseline.
How is interference from circulating drug in patient samples managed?
Residual therapeutic drug can mask ADA and generate false negatives. Common mitigation strategies include acid dissociation pretreatment to dissociate drug-ADA complexes, sample dilution at the MRD, selection of drug-tolerant platforms such as ECL or SPR, and scheduling sample collection at trough time points when drug levels are lowest.
Which regulatory documents govern confirmatory assay validation?
Key references include the FDA guidance on immunogenicity testing of therapeutic protein products, the EMA guideline on immunogenicity assessment of therapeutic proteins, ICH S6(R1) for biotechnology-derived pharmaceuticals, and USP General Chapter <1106>. Programs conducted in accredited third-party laboratories should follow GLP or GCLP principles with full data traceability.
What happens after a sample is confirmed ADA positive?
Confirmed positive samples typically proceed to titer determination to quantify relative ADA levels, and, when the drug's mechanism warrants, to a neutralizing antibody assay to assess functional blockade. These results are then integrated with pharmacokinetic, pharmacodynamic, efficacy, and safety data to characterize the clinical impact of the immune response.